Currently, there is only some evidence showing that serum B7-H4 seems to be a promising biomarker and a candidate therapeutic target for HCC, but the potential mechanism still remains elusive [19, 20]. The gene discussed is VTCN1; the disease is hepatocellular carcinoma.